HEC-265 cells were chosen because, similar to the EC tumor that harbored the endogenous A230V-ALK5 mutation, they are MSI+ (inferred) and have a similar mutation status across nine endometrial cancer genes (S2 Table). This evidence concerns the gene TGFBR1 and endometrial cancer.